Overview

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen by the tumor cells. It is not yet known whether exemestane is effective in preventing the recurrence of breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of exemestane in preventing cancer recurrence in postmenopausal women who have resected stage I, stage II, or stage IIIA breast cancer and have completed 5 years of tamoxifen.

Phase:

Phase 3

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborator:

National Cancer Institute (NCI)

Treatments:

Exemestane
Tamoxifen